AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
Public ClinicalTrials.gov record NCT06265220. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study to Evaluate the Efficacy and Safety of AB-101, an Allogeneic Cord Blood- Derived NK-Cell Therapy in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
Study identification
- NCT ID
- NCT06265220
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Artiva Biotherapeutics, Inc.
- Industry
- Enrollment
- 51 participants
Conditions and interventions
Conditions
Interventions
- AB-101 Drug
- Cyclophosphamide Drug
- Fludarabine Drug
- Rituximab Drug
- Obinutuzumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2, 2024
- Primary completion
- Jul 31, 2027
- Completion
- Jul 31, 2027
- Last update posted
- Dec 9, 2025
2024 – 2027
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Artiva Investigational Site Birmingham | Birmingham | Alabama | 35249 | — |
| Artiva Investigational Site Tucson | Tucson | Arizona | 85724 | — |
| Artiva Investigational Site San Diego | San Diego | California | 92121 | — |
| Artiva Investigational Site Aventura | Aventura | Florida | 33180 | — |
| Artiva Investigational Site Plantation | Plantation | Florida | 33324 | — |
| Artiva Investigational Site Iowa | Iowa City | Iowa | 52242 | — |
| Artiva Investigational Site Charlotte | Charlotte | North Carolina | 28625 | — |
| Artiva Investigational Site Mesquite | Mesquite | Texas | 75150 | — |
| Artiva Investigational Site Woodlands | The Woodlands | Texas | 77382 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06265220, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 9, 2025 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06265220 live on ClinicalTrials.gov.